Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults aged 19-45 years.~* BMI of \>18.5 kg/㎡ and \<27.0 kg/㎡ subject, weight more than 50kg.~* Voluntarily provided a witten consent to participate in this clinical study.~Exclusion Criteria:~* Treatment with an investigational product (Phase I study or Biological study) within 3month preceeding the first dose of study medication.~* History of (or presence) study medication absortion, distribution, metabolism(e.g., liver/ductal, kidney, cardio-vascular, endocrine, respiratory, GI, hematology, oncology, CNS, musculo-skeletal) or related past medical/surgery history~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- NVP-1805-R1 (Type: EXPERIMENTAL): Drug: NVP-1805-R1~1 tablet, oral dosing
- NVP-1805-R2 (Type: EXPERIMENTAL): Drug: NVP-1805-R2~1 tablet, oral dosing
- NVP-1805-R1 and NVP-1805-R2 (Type: EXPERIMENTAL): Drug: NVP-1801-R1 1 tablet and NVP-1801-R2 1 tablet co-administration(oral dosing)

Based on this trial design, predict the completion outcome and termination type (if applicable).